2026 Agenda: Day 1 - Monday 12 JanuaryMonday, 12 January 2026 - PT (Pacific Time, GMT-08:00)

Biotech is at an inflection point. Traditional commercialization must give way to innovative, capital-efficient models designed to accelerate market entry and maximize asset value. These experts will provide insights into emerging strategies, funding pathways, investor positioning, and lessons from recent launches. This fireside chat will offer actionable insights on risk management, value creation, and the milestones that matter most in today’s dynamic environment.

Evolving regulatory and policy dynamics are reshaping the biopharma ecosystem—impacting approval timelines, funding pathways, and market strategy. This session brings together industry and policy experts to discuss what lies ahead for biotech companies and how to navigate change to drive innovation and growth.

The Syneos Health Dealmakers’ Intentions Study is a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. Now in its 17th year, this survey provides a unique perspective on these trends by surveying business development professionals from pharmaceutical and biotechnology companies of all sizes to create forward-looking insights based on dealmakers' general expectations for activity in the coming year. This session will discuss the results of this year’s Dealmakers’ Intentions Study, providing a prospective view of the partnering and licensing landscape for the year ahead.

Join our panel of experts as they explore the latest strategies for forging successful partnerships, structuring high-impact deals, and driving collaborative innovation in the competitive landscape.